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ABSTRACT 
The aim of this study was to develop polyunsaturated fatty acid (PUFA) long chain glyceride 
(LCG) enriched self-nanoemulsifying lipidic nanomicelles systems (SNELS) for augmenting 
lymphatic uptake and enhancing oral bioavailability of docetaxel and compare its 
biopharmaceutical performance with a medium-chain fatty acid glyceride (MCG) SNELS. 
Equilibrium solubility and pseudo ternary phase studies facilitated the selection of suitable 
LCG and MCG. The critical material attributes (CMAs) and critical process parameters 
(CPPs) were earmarked using Placket-Burman Design (PBD) and Fractional Factorial Design 
(FFD) for LCG- and MCG-SNELS respectively, and nano micelles were subsequently 
optimized using I- and D-optimal designs. Desirability function unearthed the optimized 
SNELS with Temul <5 min, Dnm <100 nm, Rel15min >85% and Perm45min >75%. The SNELS 
demonstrated efficient biocompatibility and energy dependent cellular uptake, reduced P-gp 
efflux and increased permeability using bi-directional Caco-2 model. Optimal PUFA 
enriched LCG-SNELS exhibited distinctly superior permeability and absorption parameters 
during ex vivo permeation, in situ single pass intestinal perfusion, lymphatic uptake and  in 
vivo pharmacokinetic studies over MCG-SNELS. 
Keywords: PUFA lipids; docetaxel; Quality by Design; bi-directional permeability; P-gp 
efflux; Lymphatic uptake; Oral bioavailability. 
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1. Introduction 
Regardless of several innovative delivery systems and possible routes to deliver 
drugs, oral drug administration has been highly sought-after route owing to the ease of 
administration, better safety, low cost of therapy and improved patient compliance [1]. Oral 
delivery of anticancer drugs, in this context, is a key step towards providing “chemotherapy 
at home”, keeping patients out of hospitals with no needles, reduced travel/clinic time and 
decreased staffing requirements of healthcare professionals. Of late, a time and motion study 
in the UK suggested that adopting oral over intravenous chemotherapy would lead to a 7-fold 
enhancement in the number of patients treated. Besides, oral chemotherapy is particularly 
attractive in palliative setting too [2]. 
Docetaxel trihydrate (DTH), a blockbuster semi-synthetic antineoplastic drug, is 
derived from the precursor, 10-deacetyl baccatin III. It belongs to family of taxanes, primarily 
recommended for the treatment and management of diverse kinds of cancer, especially breast, 
ovarian, prostate, head, neck and small cell lung carcinomas [3]. Despite its enormous utility, 
the deliverability of DTH has been so far commercialized in the form of injectable 
formulations (e.g., Taxotere
®
, Duopafei
®
) only, with no oral product of DTH yet available in 
the market [4]. Oral delivery of DTH is known to pose multiple drug delivery challenges 
including its low bioavailability. Though with log P of 4.26 DTH should have culminated  in 
moderate permeability, but high P-gp efflux, extensive hepatic first-pass effect, considerable 
  
4 
 
gut wall metabolism by cytochrome P450 isozymes and high acid lability, coupled with poor 
aqueous solubility (0.12 mg/mL), all of which leads to hindrance in attaining the desired 
plasma levels of the drug [5].   
Although diverse oral drug delivery technologies like solid dispersions [6], inclusion 
complexes [7], cocrystals [8], lyophilized products [9], have been reported for DTH in 
literature, yet none of these formulations have yielded high degree of fruition owing to their 
limitation to solubility enhancement characteristics only. 
 Polyunsaturated fatty acids (PUFA)-based drug delivery systems have been 
increasingly investigated for improved bioavailability owing to the enhanced oral drug 
absorption. It is reported that PUFA-rich lipids containing omega-3 and omega-6 fatty acids 
solubilize the drugs due to micellization leading to absorption through lymphatic pathways. 
Despite, several investigations have been performed, yet there are barely any reports on 
PUFA rich formulations for enhancement of anticancer activity of various chemotherapeutic 
drugs including DTH till date [10, 11]. Present study was therefore taken to prepare self-
nanoemulsifying lipidic systems (SNELS) of DTH using PUFA lipids. 
Lipid-based drug delivery systems, especially the self-nanoemulsifying lipidic 
systems (SNELS) have been widely explored to surmount the challenges and issues of low 
oral bioavailability in the past a few decades [12, 13] These SNELS tend to improve the oral 
absorption by producing self-nanoemulsifying micellar systems of the drug for attaining 
desired plasma drug levels by holistically surmounting the aforesaid hiccups. The unique 
properties of lipids, namely, their physicochemical diversity, biocompatibility, and ability to 
enhance oral bioavailability of poorly water soluble lipophilic drugs through selective 
lymphatic uptake have made them attractive candidates as carriers for oral delivery [14, 15] 
SNELS also exhibits stellar features like enhanced permeability, circumvention of first-pass 
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effect due to facilitated drug absorption through lymphatic pathways, and inhibition of P-gp 
efflux, thus improving bioavailability [16]. 
Lately, holistic Quality by Design (QbD) paradigms has permeated into the general 
practice and industrial environs in order to obtain a robust and in-built quality products, as 
per the FDA recommendations [17, 18]. Considered as a science and risk-based approach, 
QbD provides rational understanding of the critical material attributes (CMAs) and/or 
critical process parameters (CPPs) affecting the critical quality attributes (CQAs) of the 
formulation. It employs the principles of quality risk management (QRM), factor screening 
and Design of Experiments (DoE) for identifying the plausible risk(s) and interaction(s) 
associated among the process and material variables [19]. Development of robust SNELS 
formulations tend to involve myriad factors, including the type, nature, chain length of lipids 
and surfactants, which influence the biopharmaceutical performance of the drug(s) [20].
 
Although there are some investigations reported on self-nanoemulsifying systems of DTH 
demonstrating improvement in its dissolution performance and oral bioavailability [21], 
however, there are hardly any reports on systematic investigation determining the effect of 
chain length of lipidic constituents on the fate of DTH permeation, absorption and lymphatic 
uptake following oral administration of SNELS, and investigating the underlying 
mechanisms responsible for it. The current research work, therefore, endeavors for systematic 
QbD-based development of the SNELS for augmenting the oral bioavailability of DTH 
employing long-chain (LC) PUFA glycerides and comparing it with medium-chain (MC) 
C8/C10 fatty acid glycerides [22, 23]. The developed lipidic formulations were evaluated 
through a series of in vitro experiments including bidirectional Caco-2 permeability model, 
cellular uptake on Caco-2 with effect of inhibitors, in situ intestinal perfusion studies and in 
vivo pharmacokinetic and lymphatic uptake studies for investigating the underlying 
mechanisms responsible for augmenting the oral bioavailability of DTH over the pure drug.  
2. Materials and methods 
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2.1 Materials 
  DTH was provided ex-gratis by M/s Cipla Limited, Mumbai, India. Capryol 90, 
Lauroglycol FCC, Lauroglycol 90, Labrasol, Maisine 35-1, Labrafac PG, Transcutol HP, 
Acrysol K160 and Labrafil 2136 were received as the gift samples from M/s Gattefosse, 
Saint-Priest, France. Tocopherol polyethylene glycol succinate (TPGS) and Peceol was 
supplied ex-gratis by M/s BASF Mumbai, India. Captex 200, Captex 300, Capmul MCM and 
Capmul PG8 were received as the gift samples from M/s Abitec Corp., Wisconsin, USA. All 
other materials and chemicals procured for the studies were of analytical grade, and were 
used as such as obtained. Animals were procured from Panjab University’s Central Animal 
House under the approval number PU/IAEC/S/14/104. 
2.2 Methods 
2.2.1 Defining the QTPP and CQAs 
  As per QbD-based paradigms, the objectives for development of SNELS were defined 
in terms of quality target product profile (QTPP) and CQAs [23]. The risk assessment studies 
were carried out to identify the CMAs and/or CPPs for DTH-loaded SNELS plausibly 
affecting the CQAs of drug product. The fishbone diagram identifies many possible causes 
for an effect or problem. Further, the risk assessment studies were carried out by constructing 
the risk estimation matrix (REM) for identifying the potential risk(s) or highly influential 
material attributes (MAs) and/or process parameters (PPs) on the CQAs of the SNELS [24]. 
The details regarding the selection of QTPP and CQAs have been elaborated in 
Supplementary Table 1 and Supplementary Table 2, respectively.       
2.2.2 Equilibrium solubility studies in lipids and emulgents 
Equilibrium solubility of DTH was determined in various lipids encompassing a 
broad spectrum of chemistry including monoglycerides/diglycerides/triglycerides mixtures, 
propylene glycol esters, fatty acid esters and fatty acids. LC lipidic excipients investigated for 
solubility studies included, Maisine™ 35-1 (a blend of partially digested long-chain 
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glycerides: 33.5% monoglycerides, 50.9% diglycerides, and 14.7% triglycerides, 
predominantly of linoleic acid (51.1%, omega-6 C18: 2) and oleic acid (32.8%, omega-9 
C18: 1) was employed to fabricate the DTH-SNELS), Peceol™ (glyceryl monooleate) 
Lauroglycol™ FCC (propylene glycol monolaurate type I), Lauroglycol™ 90 (propylene 
glycol monolaurate type II), ethyl oleate and oleic acid. MC lipids included Capmul MCM (a 
blend of partially digested medium-chain glycerides: 60.7% monoglycerides, 33.1% 
diglycerides, and 4.4% triglycerides, predominantly caprylic acid (82.8%, C8), Capmul PG8, 
(propylene glycol monocaprylate), Captex 200 (propylene glycol dicaprylate/dicaprate), 
Captex 300 (glycerol caprylate caprate), and Labrafac PG (propylene glycol 
dicaprylocaprate). Solubility of drug was also determined in surfactants, Acrysol K-160 
(polyoxyl 40-hydrogenated castor oil), Labrafil 2136 (linoleoyl polyoxyl-6 glycerides), 
Labrasol (PEG-8 glyceryl caprylate/caprate), vitamin E TPGS (d--tocopheryl polyethylene 
glycol 1000 succinate), Tween 40 (polyoxyethylenesorbitan monopalmitate) and Tween 80 
(polyoxyethylene 20 sorbitan monooleate), and cosolvents, viz. Transcutol HP (diethylene 
glycol monoethyl ether), PEG 200 and PEG 400. Shake flask method was employed to 
determine the solubility [25], wherein an excess quantity of DTH was incorporated in vials 
containing 0.5 g of different lipids and emulgents, and incubated in a water bath shaker (M/s 
Rivotec, Mumbai, India) for 72 h at 37°C with 25 strokes/min. The supersaturated mixtures 
were centrifuged at 10,000 rpm (559 × g) for 10 min in order to separate the supernatant 
fraction, which was diluted with methanol and analyzed using an already developed and 
validated UPLC method for estimating the solubilized fraction of DTH [26]. 
2.2.3 Phase titration studies 
  Water titration method was employed to construct the pseudoternary phase diagrams, 
with each of the two selected lipids, i.e., a LC PUFA glyceride (LCG i.e., Maisine™ 35-1) 
and a MC C8/C10 fatty acid glyceride (MCG i.e., Capmul MCM) with emulgent/co-solvent 
mixture (Smix in the ratios of 1:0, 1:1, 2:1 and 3:1) in the ratio varying between 1:9 and 9:1 
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w/w, to estimate the maximum nanoemulsion region. Constant visual observation and weight 
measurements were performed during titration of the lipid and Smix with water for phase 
clarity [27]. Pseudoternary phase diagrams were constructed to delineate the nanoemulsion 
region using PCP-Disso software version 3.0 (University of Bradford, West Yorkshire, UK). 
 
 
2.2.4 Factor screening studies 
  Placket-Burman Design (PBD) and Fractional Factorial Design (FFD) were employed 
to screen out “vital few” factors from “possible so many product and process variables”, in 
order to formulate LCG- and MCG-SNELS, respectively. The selected material attributes 
(MAs) finally screened were amounts of lipid, emulgent and cosolvent and the process 
parameters (PPs) were type of mixing, emulsion stirring speed, emulsion stirring time and 
temperature. The low and high levels of various MAs and PPs used during factor screening 
studies of the LCG- and MCG-SNELS are described in Supplementary Table 3 a and 3 b, 
respectively. A total of twelve formulations using PBD for LCG-SNELS, and eight 
formulations using FFD for MCG-SNELS were prepared by mixing DTH with the mixture of 
selected lipids and emulgents, and were evaluated for the chosen CQAs, viz. globule size 
(Dnm), percent drug release in 15 min (Rel15min) and percent dissolution efficiency (Temul). 
Using half-normal plots and Pareto charts, highly significant main effects were delineated 
either as CMAs or CPPs. 
2.2.5 QbD-based formulation development and optimization 
After identifying the CMAs actually influencing the performance of SNELS, I- and 
D-optimal mixture designs were employed for systematic optimization of the LCG- and 
MCG-SNELS with sixteen runs and five replicates in each design, using Design Expert
®
 
software version 9.0.1 (M/s Stat-Ease, Minneapolis, USA). The selected CMAs were 
amounts of Maisine-35-1 (LCG) and Capmul MCM (MCG) both as X1, amount of Tween 80 
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(X2) and amount of Transcutol HP (X3). The ratios of three components were adjusted to 
make the weight of upto 1 g of the formulation. DTH (20 mg) was dissolved in molten 
mixture of lipid, surfactant and cosolvent at 40
o
C, followed by vortex mixing for 5 min. All 
the prepared formulations were evaluated for Dnm, Temul, Rel15min and percent permeated in 45 
min (Perm45min) as the CQAs. Further, optimization data analysis was carried out by multiple 
linear regression analysis (MLRA) by modelling to fit in second-order quadratic polynomial 
model along with added interaction terms to correlate the CMAs with CQAs. The suitability 
of model fitness was evaluated using P-value, coefficient of correlation (R) and predicted 
error sum of squares (PRESS). The generated 3D-response surface plots enabled 
understanding of the relationship and/or interactions among the studied CMAs and their 
influence on the CQAs. 
2.3 Characterization of SNELS formulations 
2.3.1 Globule size 
  Aliquots of 1 mL of both types of SNELS formulations were diluted in 250 mL of 0.1 
N HCl (pH 1.2) and were subjected to globule size and zeta potential measurement 
employing Zetasizer ZS 90, M/s Malvern Instruments, Worcestershire, UK. 
2.3.2 Emulsification time 
  Aliquots of 1 mL of each of SNELS formulations were studied for self-emulsification 
time by pouring the liquid formulation drop wise to 250 mL of 0.1 N HCl (pH 1.2), while 
stirring at 50 rpm and maintained at 37 ± 0.5 °C, using a USP XXXI Apparatus II (DS 8000, 
M/s Lab India Instruments, Mumbai, India). 
2.3.3 Transmission electron microscopy (TEM)  
  Optimized SNELS formulations were diluted in a manner analogous to that 
mentioned in Section 2.3.2, and subsequently stained with 1% phosphotungstic acid for 1 
min, before subjecting for TEM analysis (JEM-2100 F, M/s Jeol, Tokyo, Japan). 
2.3.4 In vitro drug release 
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  Dialysis bag (12 KDa) method was employed to carry out in vitro drug release studies 
employing 250 mL of 0.1 N HCl containing 1% sodium lauryl sulphate for 1 h, stirred 
continuously at 50 rpm and 37 ± 5°C [28]. Aliquots of 5 mL were withdrawn at definite time 
points and replenished with fresh dissolution medium to maintain sink conditions, and 
analyzed by previously validated and reported method using Ultra Performance Liquid 
Chromatography (UPLC) by us [26]. 
2.3.5 Ex vivo permeation studies  
  Ex vivo permeation studies were carried out by method already been reported by us 
previously [27]. Briefly, the entire small intestine of sacrificed rats was excised and washed 
with Kreb's Ringer Buffer (KRB). Jejunum section was cut and ligated with thread to one end 
of a glass rod in order to evert it. The gut sac was filled with KRB solution and placed 
thereafter in a bath containing 50 mL of same buffer maintained at 37 ± 0.5 °C. LCG- and 
MCG-SNELS (each containing drug equivalent to 20 mg of DTH) were poured in buffer 
outside the gut sac. Aliquots of 1 mL each were withdrawn at definite time intervals, 
followed by replacement with fresh KRB solution and analyzed using UPLC to determine the 
amount of drug permeated and Perm45min. 
2.3.6 In vitro lipolysis studies 
 
In vitro lipolysis studies were performed to measure and compare the release of the 
DTH into the aqueous phase from LCG- and MCG-SNELS. As the model was designed to 
mimic the dynamic physiological conditions, previously reported by Dahan and Hoffman 
[29], where upon agitation, SNELS will form emulsion and disperse in the digestion medium. 
The model was built around a temperature-controlled (37 °C) vessel containing 100 mL of 
digestion buffer, composition of which was adapted from the previous report [29]. The 
digestion buffer contained calcium chloride, sodium chloride, sodium hydroxide, tris-maleate 
and most importantly pancreatin. 
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One gram each of LCG- and MCG-SNELS formulations (each containing 20 mg of 
DTH) was dispersed in 100 mL of prepared pre-warmed digestion buffer in order to activate 
the lipase enzyme. A pH meter was used to maintain the pH at 6.8 with 1 M NaOH 
throughout the experiment [30], i.e., for 60 min. Constant pH monitoring was required as 
triglycerides were hydrolyzed during lipolysis, to release free fatty acids, thereby decreasing 
the pH of the medium. Aliquots of 5 ml were withdrawn at periodic intervals of 0, 5, 10, 15, 
30 and 60 min and the sampled volume was replaced by blank digestion buffer. In order to 
inhibit lipolysis, the withdrawn samples were inhibited with 20 µL of 1 M 4-
bromophenylboronic acid (4-BPBA), a lipase inhibitor [31] and centrifuged at 75,000 rpm 
(6.28 × 10
5
 g) for 10 min at 4 °C in a Beckmann-Coulter Optima
TM
 MAX Ultracentrifuge 
(Fullerton, CA). Drug content was analyzed at each time point using UPLC [26]. 
2.4 Caco-2 cell line studies 
2.4.1 Caco-2 cell culture 
Caco-2 cell line (cell passages between 40 and 55) was procured from European 
Collection of Authenticated Cell Cultures (ECACC), Public Health England, Salisbury, 
England. Cells were grown in EMEM containing 2 mM glutamine, 1% (v/v) non-essential 
amino acid solution (NEAA), supplemented with 10% (v/v) heat-inactivated foetal bovine 
serum (FBS), at 37 °C in an atmosphere of 5% CO2 (ESCO, UK) in the tissue culture flasks 
(75 cm
2
; Thermo, USA). Once-cultured cells were 90% confluent, these were trypsinized 
employing 0.1% trypsin-EDTA solution. 
2.4.2 Cell viability assay 
For cell viability studies, 1 × 10
3
 cells/cm
2
 were seeded on 96-well plate (Thermo 
Fischer Scientific, Roskilde, Denmark) for overnight. Before conducting the experiment, the 
medium was aspirated from the cells, and 90 μL of both LCG- and MCG-SNELS, diluted 
with medium were added to each identified well. After 24, 48 and 72 h of treatment, 10 μL of 
PrestoBlue
TM
, a cell viability reagent (Invitrogen, MD, USA) was poured in each well, and 
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the cells were incubated for 1 h. The fluorescence was determined using a microtiter plate 
reader at the excitation/emission wavelength of 535/612 nm, respectively. 
2.4.3 Bidirectional permeability assay 
Caco-2 monolayers were grown for 19-21 days on inserts. Briefly, 
2 × 10
4 
cells/cm
2
 were seeded on sterile polyester membrane and polystyrene plates (12 mm 
diameter inserts, 0.4 μm pore size) (M/s Corning Inc., Costar®, NY, USA). On every 
alternative day, transepithelial electrical resistance (TEER; Millicell®-ERS-2 Voltohm meter, 
M/s Millipore Corporation, Billerica, MA, USA) value was measured to monitor the growth 
of Caco-2 monolayers and the extent up to, which the cellular tight junctions were formed 
[32]. On 19th to 21st day, as the cell monolayers reached the constant TEER value, i.e., 
starting from 150 ohm to about 1700 ohm, these were used for experimentation. The 
permeation of both LCG- and MCG-SNELS was studied from the apical to basolateral 
direction (A→B) and basolateral to apical (B→A) direction in Caco-2 cells. Caco-2 cell 
monolayers were equilibrated in pre-warmed HBSS at 37 °C for 30 min just before 
commencing the experiment. On the apical side, 1.0 mL of pre-warmed HBSS containing 
plain drug, and LCG- and MCG- SNELS loaded with DTH was added, each containing drug 
in the dose of 100 µmol. Subsequently, 0.5 mL of blank HBSS was added to the basolateral 
side. Similarly, the same formulations were also added on basal side and blank HBSS was 
added to apical side to better understand the permeability assay. After incubation for 0.5, 1, 2 
and 4 h, 0.2 mL of medium at the basolateral side was withdrawn and replaced with fresh 
medium to investigate A→B transport. Similarly, 0.2 mL of medium at the apical side was 
withdrawn and replaced with fresh medium for investigation of B→A transport. Drug 
concentrations from both the sides were determined by HPLC analysis and the amount of 
drug permeated, thus calculated, and was plotted as a function of time. Apparent permeability 
coefficient (Papp; cm/s) was computed from the slope of the linear plot, using the following 
equation: 
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/
                                                                                                 
….. Eq 1 
where, ΔQ/Δt is the steady state flux indicating linear appearance rate of mass in the 
basolateral side; C0 is initial concentration of drug at the apical (for A→B transport) or 
basolateral (for B→A transport); and A is the surface area of the membrane (cm2). 
 
2.4.4 Intracellular uptake and visualization 
  The qualitative uptake studies were carried out by seeding 1×10
5
 cells/well on cover 
slips in 6-well tissue culture well plates (Thermo Scientific Nunc Multidish 6, Roskilde, 
Denmark), and were allowed to adhere for overnight [32]. The cells were incubated for 0.5, 1, 
2 and 4 h with 0.078 µM Rh-123-loaded LCG- and MCG-SNELS, diluted with media. 
Following the specified incubation period, the respective cover slips on which the Caco-2 
cells adhered were removed. After washing with PBS, the cells were fixed with 
paraformaldehyde and washed thrice with PBS prior to mounting on Vectashield
®
 mounting 
medium with DAPI. Cells were observed on a modified Zeiss Cell Observer imaging system 
using Zeiss EC Plan-Neofluar 40x/1.3 Oil DIC objective. Rh-123 and DAPI were imaged 
using a GFP/DAPI filter set with excitation/emission wavelength of 450-490nm/500-550nm 
and 335-383nm/420-470nm, respectively. Analysis of the images was carried out using Zeiss 
ZEN desk imaging software for analysing the cellular uptake as a function of fluorescence 
intensity. 
2.4.5. Quantitative cellular uptake by flow cytometry 
  Cellular uptake studies were carried for evaluating the influence of time-dependent 
uptake of the developed formulations on Caco-2 cells. For time-dependent uptake, 1×10
5
 
cells/well were seeded and incubated in 6-well culture plate for overnight. At predetermined 
time intervals, i.e., 0.5, 1, 2, 4 h, cells treated with Rh-123-loaded LCG- and MCG-SNELS 
diluted with medium were removed and washed twice with PBS (pH 7.4). Further, the cells 
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were trypsinized (0.1%) and the cell extracts were centrifuged at 10,000 rpm (559 × g) for 10 
min and the supernatant was discarded. The cells were re-suspended in cold PBS and 
subjected to flow cytometry (BD FACSAria, USA) for estimating the fluorescence intensity 
employing BD filter of FITC 530/30 and PE Texas Red 610/20 employing BD FACSDiva 
software. 
 
2.4.5.1 Uptake mechanistic evaluation studies 
  To analyze the mechanism of uptake of SNELS, Caco-2 cells (1×10
5
 /well) were 
treated with various endocytosis inhibitors for 30 min prior to the experiment for selectively 
blocking the endocytosis pathways. To study the clathrin-dependent endocytosis, sucrose 
(0.45 M) was employed, while for caveolae-mediated endocytosis, cells were pretreated in 
medium supplemented with nystatin (5 µg/mL). Cytochalasin B (5 µg/mL) was used for 
assessing the macropinocytosis or phagocytosis, uptake followed by inhibition of energy-
dependent endocytosis by storing the cells-loaded with formulation at 4
0
C [33]. The cells 
were further treated and incubated with Rh-123 loaded SNELS for 1 h. Subsequent to 
experimentation; the media containing SNELS was removed and washed with PBS. Further, 
cells were made to survive in PBS, till these were viewed under live microscope for 
quantitative assessment of the intensity difference with all the inhibitors. 
2.4.6 P-gp efflux assay 
Overexpression of P-gp on Caco-2 cells is well documented in literature [34]. P-gp 
confers resistance by preventing enough accumulation of anticancer drugs within the cell, 
thereby avoiding their cytotoxic or apoptotic effects [35]. For evaluating the P-gp efflux, the 
multi-drug resistance dye efflux assay kit (M/s Chemicon International, USA) was employed. 
The efflux activity was measured to determine the intracellular accumulation of the 
fluorescent dyes, Rh-123 and DiOC2, to access the inhibitory activity of SNELS on MDR1 
and BCRP transporters, respectively. Caco-2 pellet containing 2.5 × 10
5
 cells was incubated 
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with Rh-123 alone and Rh-123 with vinblastine, Rh-123 with LCG- and MCG-SNELS 
respectively for 1 h at 37 °C. All the formulations were suspended in RPMI-1640 medium 
(M/s Sigma-Aldrich, UK). Likewise, to estimate the potential of the developed SNELS 
formulation for blocking the activity of BCRP transporters, DiOC2 dye was employed. 
Similarly, Caco-2 cells (2.5 × 10
5
) were incubated with DiOC2 alone, DiOC2 and vinblastine, 
DiOC2 with LCG- and MCG-SNELS respectively at 37 °C. The cells were washed with pre-
warmed PBS and the fluorescence intensity was measured in a TECAN fluorescence 
microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 530 
nm. 
2.5 Lymphatic uptake studies 
The lymphatic route enables the orally administered lipidic delivery systems to reach 
systemic circulation by intestinal lymphatic transport, thus evading hepatic first-pass 
metabolism through portal vein. Therefore, in vivo lymphatic uptake studies were carried out 
to investigate the extent of oral absorption of DTH from LCG- vis-à-vis MCG-SNELS [36]. 
Briefly, overnight fasted unisex Wistar rats (200-250g each) were divided into three groups, 
each group containing three animals. Various treatment formulations viz. pure drug 
suspension, LCG- and MCG-SNELS, each containing 20 mg/ml of oral dose of DTH, were 
administered to the animals through peroral route equivalent to the body weight of rats at 
dose of 20mg/kg. At predetermined time intervals of 1, 3, 6 and 12 h, the rats were 
anaesthetized by intraperitoneal injection of thiopental sodium (50 mg/kg dose), followed by 
cannulation of the mesenteric lymph duct with the help of a polyethylene tube (15 cm length, 
i.d. 0.58 mm, o.d. 0.96 mm) [37]. The lymph (approx. 0.2 mL) was periodically collected in 
eppendorf tubes at the specified time intervals and the drug was extracted by adding suitable 
volume of acetonitrile, followed by centrifugation at 10,000 rpm (2,236 × g) for 10 min. The 
supernatant organic fraction was collected and the organic phase was evaporated. The 
remaining dry residue was subsequently reconstituted in mobile phase and analyzed through a 
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previously developed and validated UPLC method of DTH in lymph. The concentration of 
drug uptaken in lymph was estimated from the calibration plot of the drug in lymph and the 
obtained data were plotted versus time. 
2.6 In situ single pass intestinal perfusion (SPIP) and histopathology studies 
  In situ SPIP were performed as per the procedure reported in literature [20]. Unisex 
Wistar rats (250-280 g), previously fasted for overnight, were used for the study. Animals 
were randomly assigned to the different experimental groups, i.e., DTH solution, DTH with 
verapamil, LCG- and MCG-SNELS respectively. Each group consisted of three animals and 
the experiments were carried out employing an in-house fabricated assembly. Anesthesia was 
induced by an intraperitoneal injection of thiopental sodium in the dose of 50 mg/kg of the 
body weight of the rats. The abdomen was incised up to 2-4 cm to create cannulated inlet and 
outlet with polyethylene tubing at proximal part on the jejunum. It was further perfused with 
lukewarm KRB solution. Subsequently, the intestine was perfused with LCG- and MCG-
SNELS, both at a rate of 0.2 mL.min
-1
. After 30 min, an aliquot of 1 mL each was 
periodically withdrawn, every 15 minutes. The perfusate was extracted with diethyl ether and 
subsequent centrifugation at 10,000 rpm (559 × g) for 10 min. Following extraction, DTH 
concentration was determined using UPLC analysis at 230 nm [26]. The permeability 
parameters like, effective permeability (Peff), wall permeability (Pwall), and absorption 
parameters like fraction absorbed (Fa) and absorption number (An) were calculated. In order 
to investigate the statistical significance difference among various parameters, one-way 
ANOVA was applied using GraphPad Prism ver 5.0 (M/s GraphPad Inc., California, USA). 
  Following perfusion studies, histopathological evaluation of the intestinal segments 
was conducted. On the excised small intestine segment, for all the groups, by fixing a part in 
10% w/v neutral buffered formalin solution for atleast 24 h. The process of fixation helps the 
tissue to prevent decomposition, putrefaction, and autolysis and withstand subsequent 
processing. Further, the tissue samples were processed by embedding these in paraffin wax, 
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which were subsequently sectioned into slices of 5 μm thickness and stained with 
hematoxylin and eosin (H&E) for microscopic examination (Olympus, Tokyo, Japan). 
2.7 In vivo pharmacokinetic studies 
In vivo single-dose pharmacokinetic studies were performed in parallel design. The 
animals were divided into three groups (n=6 each), i.e., Group I administered with pure DTH 
solution, while the animals in Group II and III were administered with LCG- and MCG-
SNELS, each at oral dose of  20 mg/kg equivalent to body weight of rats, respectively [38]. 
Formulations were administered to each rat by oral gavages and subsequently, blood (100 
µL) was withdrawn from each animal’s retro-orbital plexus at specified time intervals of 0.5, 
1, 2, 3, 6, 12, 18, 24 and 36 h. Further, plasma was extracted by centrifugation at 10,000 rpm 
(559 × g) for 10 min, and analysed for DTH using UPLC analysis [26]. 
Pharmacokinetic parameters were computed using WinNonlin software version 5.0 
(M/s ThermoScientific, USA) [20] and their statistical validity was ratified by two-way 
ANOVA using GraphPad Prism software version 5.0 (M/s GraphPad Inc., California, USA). 
3. Results and discussion 
3.1. Risk assessment studies 
 
  Supplementary Table 4 displays the risk estimation matrix (REM) constructed to 
identify the risk(s) associated with each CMAs and/or CPPs. The FMEA suggested that the 
amount of lipid, emulgent and co-emulgent were associated with high risk, while type of 
mixing process, stirring speed, stirring time and temperature were associated with medium 
risk. It depicted that type of lipids and emulgents were also associated with low risk. Based 
on the REM, the high to medium risk variables were subjected to factor screening studies for 
identifying the potential CMAs actually affecting the CQAs of SNELS formulations. 
3.2 Preliminary screening of excipients  
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  Equilibrium solubility studies revealed that mixed mono-, di-, triglycerides of both 
LCG (Maisine™, 35-1: 40.71 mg.mL-1; (Supplementary Figure 1 A) and MCG (Capmul 
MCM: 37.93 mg.mL
-1
: (Supplementary Figure 1 B) showed higher solvation capacity for 
DTH than for other lipids. This is in agreement with an earlier report, where mono-, di-, 
triglycerides have shown higher solubility for a range of drugs than the corresponding 
triglycerides [39]. Between LCG and MCG, LCG showed higher solubility probably due to 
longer lipid chain length [40] responsible for maximal solubilization of DTH. Minimum 
solubility for DTH was exhibited by Lauroglycol FCC (1.51 mg.mL
-1
) (Supplementary 
Figure 1 A) and Captex
®
 300 (1.45 mg.mL
-1
), respectively (Supplementary Figure 1 B). 
  The nonionic emulgent, Tween 80 (Supplementary Figure 1 C), was found to be most 
suitable for attaining maximal drug solubilization (85.21mg.mL
-1
) with high emulsification 
capacity and with added advantage of low toxicity during oral intake [20]. Amongst 
cosolvents, maximum solubility was exhibited by Transcutol HP (95.55 mg.mL
-1
), while 
minimum by PEG 200 (6.26 mg.mL
-1
) (Supplementary Figure 1 C). Excipients demonstrating 
highest solubility were selected to achieve high loading capacity of DTH in the SNELS 
formulation. It is already demonstrated that high solubility of drug in the SNELS is not 
merely required for maintaining the drug in a solubilized form in the oily phase of the 
resultant dispersion but also for preventing the precipitation of the drug in the gastrointestinal 
(GI) lumen after dilution with GI fluids [41]. 
3.3 Phase titration studies 
  Phase titration studies were performed with both Maisine-35-1 and Capmul MCM as 
LCG and MCG lipids, respectively, with Tween 80 and Transcutol HP as the corresponding 
surfactant-cosurfactant mixture (Smix; 1:0, 1:1, 2:1 and 3:1), in the varying ratios ranging 
between 1:9 and 9:1 for delineating the nanoemulsion region. The constructed pseudoternary 
phase diagrams delineate a good nanoemulsion region at the said Smix ratios of LCG and 
MCG, respectively. The wide nanoemulsion region can be ascribed to the efficient 
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emulsification of both the lipids in the presence of surfactant and cosolvent [20]. The 
inference drawn from the studies revealed that on increasing the amount of Tween 80 in Smix 
ratio from 1:1 to 2:1 ratios, a wider nanoemulsion region was observed (Figure 1). Further 
increase in the Tween 80 concentration narrowed down the nanoemulsion region, as is clearly 
evident from the phase diagrams for both the lipids employed for SNELS formulations. Also, 
the studies revealed that on increasing the amount of Transcutol HP in the Smix, increase in 
the nanoemulsion region was observed ostensibly due to its enhanced solubilization capacity 
and surface-wetting property. Further, it is evident from the ternary diagrams that the MCG 
formed a wider microemulsion region as compared to LCG as is illustrated in Figure 1. High 
polarity and low hydrophobicity of the MCG primarily seem to account for such a marked 
difference [42]. As MCG exhibits higher mobility characteristics on the lipid/water 
interfaces, it is documented to possess the capacity to get rapidly hydrolyzed by up taking 
large amount of water, thus forming wider nanoemulsion region [12]. On the basis of 
maximal nanoemulsion region observed during the above studies for the LCG and MCG, Smix 
ratio of 2:1 was found to be highly suitable. 
3.4 Factor screening studies 
 High and medium risk factors were screened for LCG-SNELS and MCG-SNELS 
employing PBD and FFD, respectively. Linear polynomial equations generated employing 
mathematical modeling revealed no significant interaction(s) amongst the MAs and PPs. The 
plots and charts indicated the influence of each MA/PP on the studied CQAs (i.e., Dnm, 
%DE5min, Temul, Rel15min, and MDT). Therefore, it was concluded that the values lying above 
the t-value limit and Bonferroni line are highly influential, i.e., concentration of Capmul 
MCM, Maisine-35-1, Tween 80 and Transcutol HP [Figure 2 (i) and (ii)]. Both of the lipids, 
surfactant and co-solvent showed notable effect on Rel15min, MDT, Dnm and Temul, while 
Tween 80 showed higher influence on the values of %DE5min. Hence, being highly influential, 
these factors were chosen as CMAs, and subsequently employed for systematic optimization 
  
20 
 
of both LCG-SNELS and MCG-SNELS. Further, as rest of the factors caused only negligible 
influence on the CQAs, these were fixed at constant value for subsequent optimization 
studies. 
3.5 QbD-based model development and response surface analysis (MLRA) 
  A second-order quadratic equation was generated using MLRA method, and ten 
coefficients were obtained for each of the CQAs (Eq. 2). High values of R, ranging between 
0.965 and 0.998, coupled with lower values of PRESS revealed excellent goodness of fit, 
)XX(XXβ+)XX(XXβ+)XX(XXβ+XXXβ+XXβ+XXβ+XXβ+Xβ+Xβ+Xβ=Y 32321031319212183217326315214332211  
…Eq.(2) 
 where, Y is the response variable; β1 toβ4 are the coefficients of linear model terms; β5 
to β7 are the coefficients of quadratic model terms, β8 toβ10 are the coefficients of cubic model 
terms with added interaction terms; while X1, X2, X3 represent the factors employed during 
the current optimization studies. The mathematical equations generated for each CQAs 
revealed synergism and antagonism amongst selected CMAs, depending upon the sign of the 
polynomial coefficients. 
The constructed response surface plots facilitated comprehensive understanding 
regarding influence of CMAs on the studied CQAs. The 3D-response surface plots (Figure 3 
A and 3 B) illustrate the higher influence of surfactant and moderate effect of co-solvent on 
Dnm. With increase in the levels of surfactant and cosolvent, a nonlinear trend was noticed on 
Dnm. In contrast, a linear increase was observed with increasing levels of Maisine-35-1 and 
Capmul MCM on Dnm. The smallest globule size was obtained at lower levels of lipids and 
cosolvent, and higher levels of surfactant, respectively. 
 Figure 3 C and 3 D reveal higher influence of lipids and emulgent on Temul, while the 
influence of co-emulgent was found to be insignificant. Short emulsification time was 
observed at low levels of lipids and intermediate levels of surfactants. This can be primarily 
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ascribed to the spontaneous emulsification of Maisine-35-1 and Capmul MCM in water by 
Tween 80, leading eventually to faster emulsification and lower emulsification time. 
Figure 3 E and 3 F portray 3D-response surface plot for Rel15min exhibiting a quick 
descending trend on increasing the amount of lipids, while the trend was found to be 
curvilinear with Tween 80. Moreover, increasing the concentration of Transcutol HP showed 
increase in the values of Rel15min. Overall, both the SNELS formulations showed nearly 
complete drug release within 30 min at intermediate levels of lipids and Tween 80 and high 
levels of Transcutol HP, respectively. 
Figure 3 G and 3 H depicts a response surface plot for Perm45min. A curvilinear trend 
was observed for Perm45min on increasing the levels of the lipids, emulgents and co-emulgent. 
However, the effect LCG was quite conspicuous indicating increase in the permeability with 
increase in the Maisine35-1 (Figure 3 G). The highest Perm45minwas observed at relatively 
higher levels of Maisine-35-1 and Capmul MCM and intermediate levels of Tween 80 and 
Transcutol HP. 
By and large, prevalence of distinct nonlinear trends in these response surfaces 
unequivocally indicate involvement of interactions among the studies excipients, thus 
corroborating the remarkable utility and superiority of systematic QbD-enabled paradigms 
over the traditional one variable at one time (OVAT) approach.   
3.6 Characterization of the prepared LCG and MCG SNELS 
3.6.1 Globule size measurement 
The mean globule size for all the SNELS prepared as per the experimental design, 
were found to range between 15 and 110 nm, affirming the nanostructured character of the 
developed SNELS containing either LC or MC lipids. However, the mixed micelles of LCG-
SNELS were observed to be significantly larger (101 nm; P<0.001) Supplementary data 
Figure 2 A) than MCG-SNELS (16 nm; Supplementary data Figure 2 B). The LC lipids have 
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already been reported to result in polydisperse emulsions with significantly lower size [43] 
ascribed to their longer fatty chain length than that of MC lipids. Further, the smaller globules 
were found to be formed at lower concentrations of lipid, higher concentrations of surfactant 
and intermediate concentrations of cosolvent present in the formulations. Varying the 
proportions of surfactant and co-surfactant, attributed the condensation and stabilization of 
interfacial film, resulting in the formation of smaller droplets, in consonance with previous 
findings [44]. However, on adding more of co-surfactant the film generally expands and 
increases the globule size [45]. 
3.6.2 Self-emulsification time 
Temul values of all the formulations ranged between 135 and 205 sec (i.e., < 5 min) for 
both LCG- and MCG-SNELS. Lower values of Temul indicated spontaneity of emulsification 
producing nanoemulsions with transparent bluish tinge. In general, formulation containing 
higher concentration of Tween 80 exhibited faster emulsification leading to absolute 
miscibility of lipids in the aqueous phase by micellar solubilisation [41]. 
3.6.3 In vitro drug release studies 
Figures 4 (A) and 4 (B) portray the in vitro release profiles of DTH from LCG 
SNELS and MCG SNELS, respectively using dialysis bag method. Almost 80% of drug 
release was observed within first 30 minutes, and nearly 90% drug released within 1 h. Since 
in vitro dissolution profiles observed for both the types of LCG- and MCG-based 
nanoemulsified formulations were almost analogous, the lipid chain length was not found to 
affect the drug release from the SNELS appreciably [27]. However, it was interesting to note 
that the formulations with higher levels of surfactants released the drug faster and better [27].  
3.6.4 Zeta potential studies 
The values of zeta potential for LCG- and MCG-SNELS were found to be -29.8 mV 
and -35.0 mV, respectively (Supplementary Figure 3). Indicative of the degree of repulsion 
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between adjacent and similarly charged particles, zeta potential tends to delineate the stability 
potential of the formulation [27]. Nanosized systems characterized by high values of zeta 
potential have been reported to be highly stable by virtue of their resistance against 
aggregation and/or coalescence [20]. 
 
 
3.6.5 Ex vivo permeation studies 
The ex vivo permeation of optimized formulation in 45 minutes was found to be more than 
approximately 85% for LCG SNELS and 70% for MCG SNELS, which can certainly be 
attributed to the enhanced absorption of LCG SNELS owing to its longer chain length [20]. 
3.7 Search for the optimum formulation and validation of QbD 
Various CQAs were “traded off” to attain the desired objectives, i.e., smaller Dnm, 
minimum Temul, with maximum release in 15 min (Rel15min) and higher permeability in 45 
min (Perm45min). In order to attain the stated objectives, the selection criteria embarked upon 
to search the optimized formulation were Temul< 5 minutes, Dnm< 100 nm and Rel15min>80%. 
Numerical optimization methodology was carried out for identifying the optimum 
formulation, where all the CQAs exhibited desirability close to unity. Further, Figure 4 C and 
4 D portray the optimum formulations of LCG- and MCG-SNELS demarcated in the design 
space overlay plot. The optimum LCG-SNELS contained Maisine-35-1 (338 mg), Tween 80 
(434 mg) and Transcutol HP (227 mg), with the values of CQAs as Dnm of 98 nm, Temul of 1.3 
min, Rel15min of 75% and Perm45min 82%. On the other hand, the optimum MCG-SNELS 
contained Capmul MCM (353 mg), Tween 80 (440 mg) and Transcutol HP (205 mg), with 
the values of CAQs as Dnm of 106 nm, Temul of 1.2 min, Rel15min of 84% and Perm45min of 
60%. Also, TEM imaging (Figure 4 E) of optimized LCG-SNELS revealed the size range 
between 60.4 and 70.7 nm, while MCG-SNELS exhibited the size range of 11.7 to 21.0 nm 
[Figure 4 (F)]. 
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3.8 In vitro lipolysis studies 
 
In vitro digestion profile of DTH-loaded LCG- and MCG-SNELS was investigated in the 
prepared bio-relevant dissolution media followed by UPLC analysis for the fraction of 
solubilised DTH in the aqueous phase. The rate of digestion of SNELS by pancreatic lipase 
was estimated by measuring the consumption of sodium hydroxide (NaOH) needed to 
neutralize the released fatty acids during lipolysis. The rate and extent of digestion and the 
phase behavior of the lipolytic products is markedly dependent on the fatty acid chain length.  
Similar to previous report by Sek and associates [46], post 30 minute lipid digestion on 
ultracentrifugation, the MCG-SNELS (Figure 5 C-i) showed complete digestion, separating 
into two distinct phases, i.e., aqueous and pellet fraction in a bile-salt-independent manner. 
The LCG-SNELS (Figure 5 C-ii), on the other hand, got separated into three phases, i.e., oily 
(i.e., containing undigested triglyceride and diglyceride), aqueous (i.e., containing bile salt, 
fatty acid and monoglyceride), and a pellet phase (i.e., containing fatty acid, presumably as 
an insoluble soap). However, digestion for both the formulations was observed to be quite 
fast at early time points. Maisine-35-1 and Capmul MCM, both being the lipase substrates 
[47], exhibited similar lipolysis rates as indicated by insignificant difference (P>0.01) in 
NaOH consumption of LCG- and MCG-SNELS (Figure 5A) [48]. The release of DTH from 
both these SNELS formulations (Figure 5 B) showed a similar release pattern without any 
significant difference (P> 0.05)  
3.9 Caco-2 cell line assays 
3.9.1 Cell viability assay 
 
Quite often, there could be impairment of Caco-2 monolayers, plausible ascribable to 
cytotoxicity of lipids and/or surfactants, eventually leading to false reporting of augmentation 
in drug permeation. Therefore, it is essential for any promising lipidic formulations to have 
good tolerance at the site(s) of absorption, and quite vital to test the optimum formulations for 
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cytotoxicity prior to further biological investigation [49]. Figure 6 (A, B and C) depicts the 
log concentration versus percent viability profile for the Caco-2 cells incubated with free 
DTH, LCG- and MCG-SNELS, respectively. PrestoBlue was used as the cell viability 
indicator as it is considered to yield consistent, reliable and quicker results than other 
reagents [50]. The percent cell viability for Caco-2 cells with PrestoBlue was found to be 
>96% for formulations of both the types of lipid and at all the studied concentrations, i.e., 10, 
25, 50, 75, 100, 250, 500 and 1000 µmol, without any significant change (p>0.05) between 
these. The studies ratified the safe and biocompatible nature of the developed SNELS. 
3.9.2 Bidirectional permeability assay 
 
In vitro bidirectional Caco-2 model has been extensively explored to investigate the 
intestinal absorption and cytotoxicity of the drugs and their formulations, as these cells 
differentiate into functionalized epithelial barrier [51]. Further, it was indeed important to 
access the permeability of the formed nanomicelles across the intestinal epithelial barrier. 
DTH being quite prone to P-gp efflux [52], the strategy adopted in the current studies was not 
only to study the A→B permeation but also to investigate the B→A transport. The 
bidirectional permeability assay was carried out for determining the concentration of DTH in 
the apical and basolateral compartments following incubation of the Caco-2 cells with 
different treatments. As DTH is a substrate of P-gp, it tends to efflux out from the cells, thus 
leading to drug resistance. Figure 6 D illustrates the apparent permeability (Papp) of DTH 
during the bi-directional permeability studies performed for different treatment formulations 
at varied time-points. Since the cells were seeded, the TEER value was constantly monitored 
to predict the growth of the monolayer of Caco-2, while measurement during the 
experimentation was performed to investigate any possible damage of the formed monolayer 
[53]. The recorded TEER values for growing monolayer increased from 150 to 1600 Ω•cm2 
in around 21 days. Further, on incubation with all the treatments, significant reduction 
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(<10%; P<0.05) in TEER values was observed vis-à-vis the control cells, indicating that the 
formulations affect tight junctions [54]. This can be ascribed to the presence of polysorbate, 
which has already been documented to affect the tight junctions of the Caco-2 monolayers 
and thus account for paracellular transport [55].  
The results revealed that nanomicelles formed from the DTH-loaded SNELS showed 
a six-fold increase in permeation (Papp, 12.9 × 10
–6
 cm/sec) as compared to plain DTH 
solution (Papp, 1.9 × 10
–6
 cm/sec) within 4 h of the studied time period (Figure 6 D). This 
construed enhancement in permeability of DTH-loaded SNELS, is ascribable to lipidic and 
emulsifying excipients employed for the preparation of SNELS. Such excipients tend to 
improve the permeability of drug ostensibly owing to their lipophilic nature along with ability 
to form nanomicelles after emulsification in aqueous phase [56]. Moreover, higher 
permeability of SNELS across the Caco-2 cells can be related to the P-gp efflux pump 
inhibition, governing the transport and permeability of DTH from the SNELS [57]. 
Interestingly, it was observed that Papp increased with time, which could be attributed to the 
ability of Tween 80 [58] and Transcutol HP [21] to block the P-gp efflux across the intestinal 
barrier, resulting consequently in increased permeation with time [32]. 
The results also clearly demonstrated the superiority of LCG-SNELS to MCG-SNELS 
owing to the longer chain length of the lipids employed in the former, which facilitate faster 
internalization of the drug molecules across the membrane of Caco-2 cells. Additionally 
PUFAs are known to cause reduction in pump activity of MDR1/P-gp which would have 
contributed to increased permeability of  LC PUFA based SNELS [59]. Effux ratio of DTH,  
a known P-gp substrate [60], was reduced to 0.20 and 0.25, when administered as LCG- and 
MCG-SNELS, respectively compared to 0.84 for the drug alone. This could be assigned to 
inhibition of P-gp triggered efflux by Tween 80 [61] and Transcutol HP [62], and the 
increased permeability owing to nature of lipidic excipients and their characteristic chain 
length.  
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Overall, the Caco-2 cells studies revealed that SNELS can augment the permeation of 
DTH owing to P-gp efflux inhibition and facilitate faster permeation across the Caco-2 cells 
for enhanced drug bioavailability. 
3.9.3 Qualitative and quantitative cellular uptake 
 
Figure 7 depicts the fluorescent images of Caco-2 cells incubated with various 
formulations labelled with fluorescent dye Rh-123. Figures 7 B and 7 C reveal the presence 
of fluorescence inside the cells treated with Rh-123-loaded MCG- and LCG- SNELS at 1 h, 
which later increased remarkably at 4 h (Figures 7 D and 7 E), thus substantiating the time-
dependent and efficient internalization of sub-micron emulsion droplets by Caco-2 cells. 
Also, the qualitative estimation of the fluorescence intensity divulges superior uptake 
potential of LCG-SNELS (Figure 7 C and 7 E) to MCG-SNELS (Figure 7 B and 7 D) 
corresponding to the same time-points. The quantitative flow cytometry results showed time-
dependent increase in fluorescence for both the LCG- and MCG-SNELS (Figure 7 F), 
indicating maximum cellular uptake at 4 h. The results observed from the uptake studies were 
found to be in consonance with the permeability studies, thus corroborating the superiority of 
LCG-SNELS over the MCG-SNELS for potentiating drug absorption of DTH. 
3.9.4 Mechanism of cellular uptake 
 
The endocytosis of a nanoparticle is an active and energy-dependent process, which can be 
inhibited by low temperature. Therefore the difference in cellular uptake at 37 °C and 4 °C at 
1 h was qualitatively and quantitatively compared via fluorescence microscopy and flow 
cytometry assay. The relative intracellular fluorescence percentages of both the SNELS at 
37 °C were significantly greater than that at 4 °C at the given time point, i.e., 1 h (Figure 8 B 
and 8 C). More precisely, the cellular uptake at 37 °C was about 12- and 10-folds higher than 
that at 4 °C for LCG- and MCG-SNELS at 1 h, respectively (Figure 8 G). It has been 
reported that the active transportation on cell membranes significantly reduces at 4 °C [63]. 
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Therefore, the studies demonstrate that the endocytosis of SNELS by Caco-2 cells to be 
energy-dependent, involving an active process [64]. 
To elucidate the cellular trafficking pathway of SNELS different inhibitors blocking specific 
pathway were used. Hypertonic sucrose induces abnormal clathrin polymerization into empty 
microcages rendering clathrin unavailable for assembly into normal coated pits and inhibits 
endocytosis. Nystatin, a known inhibitor of caveolae-mediated endocytosis profoundly 
distorts the structure and functions of the cholesterol-rich membrane domain, including 
aberrations in the caveolar shape while cytochalasin A causes depolymerisation of the actin 
filaments thus disrupting the actin-mediated macropinocytosis. An endeavor has been made 
to qualitatively and quantitatively understand the mechanistic pathways through measurement 
of intensity of the fluorescence of internalized Rh-123 loaded SNELS after treatment with 
these pharmacological inhibitors. Figure 8 A illustrates the image for the control cells, while 
Figure 8 B reveals the intensity of fluorescence after 1 h incubation of Caco-2 cells with the 
LCG- and MCG-SNELS formulations without any inhibitor. On the contrary, Figure 10 D to 
F reflects the fluorescence intensity within cells when treated with the three types of 
inhibitors, viz. sucrose, nystatin and Cytochalasin B. The results demonstrate that none of 
inhibitors had any effect on endocytosis of SNELS. The SNELS internalization was not 
mediated through any of these pathways. The flow cytometry (FCM) analysis endorsed these 
results with insignificant impact (P>0.05) on cellular uptake of SNELS, indicated by nearly 
constant fluorescence intensity of cells following treatment with the endocytosis inhibitors 
(Figure 8 G), in concurrence with a previously reported study [65]. These findings are also 
supported by another report by Song and associates [66], which showed pegylated polyester 
nanoparticles to undergo an energy-dependent, lipid raft-mediated, but caveolae-independent 
endocytosis in Caco-2 cells. Cellular uptake of LCG- and MCG-SNELS was found to be an 
energy-dependent process, but internalization occurred in a clathrin- and caveolae-
independent manner.  
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3.9.5 P-gp efflux assay 
The P-gp efflux assay revealed that both the dyes (i.e., Rh-123 and DiOC2), were 
effluxed out at 37 °C, as evident from lack of intracellular accumulation of the fluorescent 
dye (Figure 9 A). On the other hand, incubation with P-gp efflux inhibitor, i.e., vinblastine 
showed that dyes may have coupled with vinblastine, thus blocking MDR1 and BCRP 
transporters, both at 37 °C, eventually leading to higher fluorescence intensity without any 
efflux. Both LCG- and MCG-SNELS interfered with the microenvironment of P-gp and 
weakened the P-gp mediated efflux, as apparent from higher accumulation of Rh-123 and 
DiOC2 dyes, suggesting MDR1 and BCRP transporters were not functional. Accordingly, the 
excipients of both SNELS play a major role in inhibiting the P-gp efflux and significantly 
reduced transporter efficiencies for the P-gp substrate, i.e., Rh-123 and DiOC2 dyes.  
Previous reports have shown intact internalization of self-nanoemulsifying system into Caco-
2 cells bypassing P-gp recognition [67]. 
3.10 Lymphatic uptake studies 
 
  Figure 9 B illustrates the lymphatic uptake of DTH after oral administration of 
various test formulations with respect to time. Highly statistically significant difference (p < 
0.001) in the lymphatic uptake of LCG-SNELS was observed from the MCG-SNELS and 
pure DTH at all experiment time points, when administered orally in rats. LCG-SNELS 
showed maximal uptake (i.e., up to 3.79-fold) from the lymph in 3 h, while the MCG-SNELS 
showed nearly 2.26-fold improvement in lymphatic uptake vis-à-vis pure drug suspension. 
Significant improvement in the uptake of drug in lymph from LCG-SNELS can be ascribed 
to the faster absorption and transportation of the drug preferentially through intestinal 
lymphatic pathways [13]. The lipids, whether LCGs or MCGs, not only facilitate the 
solubilization of drugs exhibiting low solubility and lipophilicity, but also increase the 
fraction of drug transported via intestinal lymphatic system, thereby increasing absorption 
from the GI tract, depending upon the chain length of lipids [68]. The superiority of the LCG- 
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over MCG-SNELS could be attributed to the transit of LCGs as long-chain fatty acids and 
monoglycerides across the intestinal cell, where these are re-esterified to triglycerides and 
further incorporated into chylomicrons to be secreted from the intestinal cell by exocytosis 
into the lymph vessels [69]. Whereas, MCG is transported to portal blood before going to 
systemic circulation, where the later encounter first-pass metabolism, thus accounting for the 
reduced concentration of DTH in lymph [70]. However, the reasonable response of MCG is 
also ascribable to the formation of medium-chain saturated fatty acids, which are 
resynthesized or re-esterified to triacylglycerols or neutral lipids, packaged within apoprotein 
surface layers and again transported via the lymphatic system [71]. Hence, it can be 
concluded that a multitude of factors tend to influence the lymphatic absorption of drugs, 
including lipid chain length, partition coefficient, and above all, the formation of 
chylomicrons produced after digestion of lipid-based systems to facilitate higher fraction of 
drug to be transported through the intestinal lymphatic system, and subsequent drainage into 
the systemic circulation [72]. 
  These findings are consistent with previously published work, where MCGs are 
reported to be more likely to be taken up into the portal system, whereas the LCGs, are 
directly taken up into the lymphatic system as triglycerides [33]. The long chain fatty acid 
also facilitate the absorption of the drug through lymphatic pathways by circumnavigating the 
hepatic first-pass effect, thus helping in enhancing the distribution of the drug to the 
lymphatic system with consequent improvement in oral bioavailability of lipophilic drugs 
[13]. 
3.11 In situ single pass intestinal perfusion studies (SPIP) 
  The in situ SPIP studies are well known model to investigate the absorption and 
permeation behavior of a drug, when administered using self-nanoemulsifying systems.  With 
LCG- and MCG-SNELS, much higher magnitudes of absorptivity and permeability 
parameters were observed vis-à-vis pure DTH. As is evident from Figure 9 C, LCG- and 
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MCG-SNELS showed significant improvement (P < 0.001) in the absorption number (An) by 
4.5- and 3.6-fold as compared to the pure drug, respectively [14]. The value of An indicates 
the amount of drug transferred across the GI tract, where both the SNELS were found to be 
highly superior to free drug indicating improved drug absorption characteristics. Further, 
marked increase (P <0.01) in the magnitude of fraction of drug absorbed (Fa) was observed 
for LCG-SNELS (i.e., 4.1-fold) and MCG-SNELS (i.e., 3.0-folds) vis-à-vis pure drug, 
indicating notable augmentation in the absorption potential of the drug through SNELS, 
ostensibly owing to the potentiation of drug absorption through lymphatic pathways by 
circumnavigating the hepatic first-pass effect [73]. 
  Similarly, in case of the permeability parameters, the effective permeability 
(Peff) also showed nearly 4.0- and 3.2-fold improvement by the LCG- and MCG-SNELS (P < 
0.001 each) vis-à-vis the pure drug. Further, the SNELS formulations also showed 
considerably increased (P < 0.01) values of wall permeability (Pwall), i.e., 3.1-fold by LCG-
SNELS, while 2.4-fold by MCG-SNELS, vis-à-vis the pure drug. The presence of surfactant, 
Tween 80 in the nano micellar formulations may have induced membrane perturbation and P-
gp inhibition that enhanced the drug permeability [74].  ween  0 having both lipophilic and 
hydrophilic properties, partitions between lipid and protein domains in the intestinal 
membrane disrupting its integrity and plausibly increasing the permeability of DTH [75]. 
Further Tween 80 is known to modulate the P-gp efflux by inhibition of protein kinase C 
activity and thereby reducing the phosphorylation of P-gp [76]. 
P-gp efflux pump expressed all along the gastrointestinal tract limits permeability of many 
drugs and affects their peroral absorption and bioavailability. Verapamil being a potent P-gp 
inhibitor was able to improve the permeation and absorption parameters of DTH but up to a 
limited extent [77]. The values of An and Fa were found to be significantly improved by 3.1- 
and 2.9-folds, for LCG-SNELS and 2.5- and 2.1-folds for MCG-SNELS vis-à-vis DTH in 
presence of verapamil (P <0.01 each). Similarly, the magnitudes of Peff and Pwall increased 
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by 2.2- and 1.7-folds, and 2.2- and 1.5-folds for LCG- and MCG-SNELS, respectively, with 
verapamil vis-à-vis pure drug (Figure 9 C). The superior values of Peff and Pw construed 
increase in the permeability and uptake characteristics of the drug using SNELS, plausibly 
owing to the enhancement in permeability of drug and inhibition of efflux by P-gp and/or 
BCRP transporter owing to the presence of lipidic and emulsifying excipients in the 
formulations, in agreement with literature [78]. Besides, the results also showed higher 
magnitude for enhancement in the permeability parameters by SNELS containing LCGs, 
plausibly owing to being omega-6 PUFA glyceride along with its higher chain length and 
lipophilicity as compared to the MCGs. By and large, the LCG-SNELS showed around 1.3-
and 1.3-folds and 1.4 and 1.3-folds augmentation in Peff, Pwall, Fa and An, respectively (P 
<0.05 each) as compared to MCG-SNELS. Previous reports have shown enhanced intestinal 
permeability [79] and improved oral bioavailability with LC (C18) self-emulsifying systems 
[80]. LCGs form larger mixed micelles than MCGs on digestion, which tend to have a higher 
drug solubilizing capacity leading to higher permeability and bioavailability [12]. Caliph and 
associates [81] have also  demonstrated the effect of chain length on the permeability across 
the lymph  
Further, the histopathological analysis was carried out for the intestine after perfusion 
experiment from each group of rats. Figure 9 D (i-iv) depicts the microscopic images of the 
rat’s small intestinal segments after exposure to (i) Control (ii) Plain DTH (iii) LCG-SNELS 
(iv) MCG-SNELS. Gut segments treated with the aforementioned formulations revealed 
normal intestinal morphology, i.e., intact brush border and villi, without any significant 
pathological change(s). Also, the lymphoid follicles and submucosa were found to be normal, 
thus ruling out any potential toxic effects. In line with Caco-2 PrestoBlue cell viability assay, 
the histopathological evaluation accordingly revealed safe and biocompatible nature of both, 
LCG- and MCG-SNELS. 
3.12 In vivo pharmacokinetic studies 
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Figure 9 E depicts the plasma concentration versus time profiles of DTH, LCG-
SNELS and MCG-SNELS in each group (n=6). On applying one-way ANOVA, significant 
statistical difference (P<0.01) was observed among the individual plasma concentrations of 
both the SNELS in contrast to pure drug. The linear decline in the post-Tmax log concentration 
time data further corroborated the suitability of two-compartment model kinetics. The results 
observed from the current studies are in accordance with the literature report [27]. 
Analysis of the in vivo pharmacokinetic studies in rats as per chosen two-
compartment open body model (2-CBM), exhibited much higher oral bioavailability in terms 
of extent and rate of absorption, as depicted from various pharmacokinetic metrics like AUC, 
Cmax, Tmax and Ka, by LCG- and MCG-SNELS vis-à-vis free drug suspension (Table 1). 
Nearly 11- and 4.6-folds improvement in AUC and Cmax, and 2.3-fold reduction in 
Tmax was observed for the LCG-SNELS vis-à-vis DTH suspension, respectively. Similarly, 
for MCG-SNELS, 8.7- and 1.8-folds augmentation in AUC and Cmax, coupled with 1.2-fold 
reduction in Tmax values, ratified distinct improvement in the rate and extent of oral 
bioavailability (p <0.001), when compared with pure DTH suspension. The LCG SNELS and 
MCG SNELS also showed improvement (1.9- and 1.2-folds) in the values of Ka vis-à-vis free 
drug suspension, respectively.  
On the whole, the pharmacokinetic studies revealed superiority of formed LCG- over 
MCG-SNELS in increasing the oral absorption of DTH. There are several studies reported in 
literature indicating that drugs from formulations containing LCGs and MCGs are transported 
differently in the body [20, 39, 56]. Porter and Charman have reported that MCG is directly 
transported by the portal blood to the systemic circulation, whereas LCG is transported in the 
intestinal lymphatics. Therefore, lipid-based drug delivery systems containing LCGs are 
likely to enhance the lymphatic transport of a lipophilic drug substance like DTH (log P 4.26) 
because the lymphatic transport circumnavigates the hepatic first-pass metabolism of a drug. 
The LCG based formulations have been previously reported to furnish higher oral 
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bioavailability vis-à-vis their MCG-couterparts [81]. In a nutshell, the oral bioavailability of 
DTH using LC PUFA glycerides SNELS will be enhanced due to combined effect of 
improved solubility, inhibition of P-gp efflux along with increased intestinal lymphatic 
transport of drug with consequent reduction of first pass metabolism. Figure 10 portrays the 
mechanism of uptake of LCG- and MCG-SNELS through intestinal uptake. 
 
 
 
 
4. Conclusions: 
 
The SNELS formulations prepared in the present studies demonstrated significant 
improvement in the biopharmaceutical attributes of DTH, a BCS class drug exhibiting poor 
aqueous solubility, low permeability and oral bioavailability. Application of QbD-based 
systematic development of LCG- and MCG-SNELS resulted in comprehensive understanding 
of the formulation and its process parameters. Among the various LCGs and MCGs 
investigated for preparing SNELS, the LCG constituting PUFA showed remarkable 
improvement in enhancement of its dissolution with inhibition of the P-gp mediated efflux 
and by passing first pass effect, resulting consequently in improved oral bioavailability as 
vividly examplified in the in vivo pharmacokinetic studies. Also, its increased permeability 
and absorption parameters during ex vivo permeation and in situ perfusion studies have been 
illucidated. The superiority of the LCG- over MCG-SNELS was also well demonstrated in 
lymphatic uptake studies attributed to re-esterification of LCGs to triglycerides and their 
incorporation into chylomicrons and secreted from the intestinal cells into the lymph vessels. 
In vitro lipolysis studies indicated significant difference in the release of free fatty acids and 
digestion between the LCG and MCG SNELS formulations. The MCG SNELS, having the 
shorter lipidic chain length than LCG SNELS was more completely digested. Cytotoxicity 
and uptake studies on Caco-2 cells revealed safe and biocompatible nature of the 
nanomicellar formulations along with efficient energy dependent cellular uptake which was 
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independent of clathrin- and caveolin- mediated endocytic pathways. Overall, the studies 
corroborated enormous utility of SNELS especially prepared using LC PUFA glycerides in 
augmenting the oral bioavailability of DTH. The outcome of the current studies and 
mechanistic unravelled can successfully be extrapolated to other BCS Class II and IV drugs. 
Future studies will involve understanding the potential of these formulations in cancer 
therapeutics by investigating their cellular ineteraction in mamalian cancer cells and efficacy 
in suitable animal tumor model. 
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Figure captions: 
Figure 1: Ternary phase diagrams: (A-D) Long chain glycerides: LCG (with Smix ratios of (A)1:0; (B)1:1; (C) 
2:1; (D) 3:1 and (E-H) Medium chain glycerides: MCG (with Smix ratios of (A) 1:0; (B) 1:1; (C) 2:1; 
(D) 3:1. 
Figure 2(i) Half-normal plots and Pareto charts extracted resulting after application of Placket-Burman design 
for long chain glycerides self-nanoemulsifyinglipidic systems (LCG-SNELS) depicting the influence of 
material attributes (MAs) and process parameters (PPs) on the critical quality attributes (CQAs), (A) 
globule size: Dnm, (B) percent dissolutionefficiency in 5 min: %DE5min, (C) emulsification time: Temul, 
(D) Drug release in 15 min Rel15min (E) Mean dissolution time: MDT. 
Figure 2(ii) Half-normal plots and Pareto charts resulting after application of Fractional factorial design medium 
chain glycerides self-nanoemulsifyinglipidic systems (MCG-SNELS) depicting the influence of 
material attributes (MAs) and process parameters (PPs) on the critical quality attributes (CQAs), (A) 
globule size: Dnm, (B) percent dissolution efficiency in 5 min: %DE5min, (C) emulsification time: Temul, 
(D) drug release in 15 min: Rel15min (E) mean dissolution time: MDT. 
Figure 3: 3D-Response surface plots showing the influence of (A) Maisine-35-1, (B) Tween 80, (C) Transcutol 
HP on the CQAs viz.(i) globule size (Dnm), (iii) emulsification time (Temul), (v) percent drug release in 
15 min (Rel15min), (vii) permeability in 45 min (Perm45min); Likewise, the other 3-D response surface 
plots show the influence of (A) Capmul MCM, (B) Tween 80, (C) Transcutol HP on the CQAs viz. (ii) 
globule size (Dnm), (iv) emulsification time (Temul), (vi) percent drug release in 15 min (Rel15min), (viii) 
permeability in 45 mins (Perm45min). 
Figure 4: Cumulative in vitro drug release profile of DTH from (A) LCG SNELS and (B) MCG SNELS 
formulations prepared as per the I- and D-Optimal Mixture design, respectively; Values expressed in 
mean ± SD (n=3). 
Design space overlay plot for optimized (C) LCG-SNELS and (D) MCG-SNELS across the two-
dimensional experimental domain; TEM image of (E) LCG-SNELS and (F) MCG-SNELS. 
Figure 5 (A) Comparative consumption of NaOH as a function of time for LCG and MCG SNELS (mean ± SD, 
n = 3) (B) The % of DTH release from both the SNELS formulation into the aqueous phase as a 
function of time (mean ± SD, n = 3) (C) Appearance of both the formulations after lipolysis (i) MCG 
SNELS (ii) LCG SNELS. 
Figure 6: Cell viability assay on Caco-2 cells following treatment with DTH, LCG- SNELS and MCG-SNELS 
at (A) 24 h, (B) 48 h, (C) 72 h. (D) Bidirectional permeation study of various formulations of DTH on 
Caco-2 cells. 
Figure 7: Fluorsecent images of time dependent cellular uptake at (A) Control cells, (B) MCG-SNELS at 1 h, 
(C) LCG-SNELS at 1 h, (D) MCG-SNELS at 4 h, (E) LCG-SNELS at 4 h; (F)Fluorescence intensity at 
various time points for Rh-123 loaded LCG- and MCG-SNELS in Caco-2 cells, a quantitative 
measurement. 
Figure 8: Influence of different endocytosis inhibitors on cellular uptake of Rh-123 loaded LCG- and MCG-
SNELS at 1h in Caco-2 cells, a qualitative measurement; (A) Control cells (B) without presence of 
inhibitor (C) at 4°C; after treatment with (D) Sucrose (E) Nystatin (F) Cytochalasin B; (G) 
Fluorescence intensity at 1h for Rh-123 loaded LCG- and MCG-SNELS in Caco-2 cells after treatment 
with various endocytotic inhibitors, a quantitative measurement. 
Figure 9: (A) Effect of LCG- and MCG-SNELS on efflux of MDRI transporter Rh-123 and BCRP 
transporterDiOC2 as measured by fluorescence in Caco-2 cells (B) Lymph drug concentration (µg/mL) 
of LCG- and MCG-SNELS vis-a-vis plain DTH; (C) Percent increase in the permeability paramaeters 
(i.e., Peff and Pwall), and absorption parameters (i.e., Fa and An) of LCG-SNELS and MCG SNELS vis-
à-vis pure DTH and DTH with verapamil; (D) Histopathology of small intestine: (i) Control (× 200); 
(ii) Plain DTH (× 200); (iii) LCG-SNELS (× 200); (iv) MCG-SNELS (× 200); Small intestine showing 
normal tall villi and intact brush borders. No other significant pathological changes were observed; (E) 
Plasma concentration time profile versus time for optimized LCG- and MCG-SNELS vis-à-vis pure 
DTH. 
Figure 10: Diagram portraying the intestinal uptake of LCG- and MCG-SNELS  
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Table captions: 
Table 1: Pharmacokinetic parameters of DTH obtained from plasma level studies in rats after oral administration 
of various treatment formulations 
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Table 1: Various compartmental modelling parameters 
 
Treatment 
Formulations 
Pharmacokinetics metrics 
Cmax 
(ng mL
-1
) 
AUClast 
(ng.h/mL
-1
) 
Ka (h
-1
) Tmax (h) MRT (h) 
LCG-SNELS 1597.2 ± 59.4 9197.7 ± 46.9 0.213 ± 0.023 1.42 ± 0.28 18.47 ± 2.56 
MCG-SNELS 612.5 ± 78.4 7425.8 ± 66.9 0.141 ± 0.021 2.74 ± 0.42 16.56 ± 1.45 
DTH 346.9 ± 58.4 847.2 ± 106.0 0.112 ± 0.013 
 
3.27 ± 0.30 11.56 ± 1.45 
Data represented as Mean ± SD (n=3) 
 
 
 
